|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1200 - 0.3500|
|52 Week Range||0.1200 - 0.7700|
|Beta (3Y Monthly)||4.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2019 - May 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.21|
Parnell Delivers 9% Revenue Growth in Quarter 1 of 2019 Compared to 2018, and Confirms Provisional 2019 Guidance for a 17 - 25% Increase Over 2018 Revenue to $31 - $33 Million and an EBITDA Range of $7.5 ...
SYDNEY, AUSTRALIA / ACCESSWIRE / April 30, 2019 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing ...
Parnell Delivers 39% Revenue Growth and a $6.5 Million Improvement in EBITDA in 2018 Compared to 2017, Returns to NPAT Profitability, and Provides Provisional 2019 Guidance For a 17 - 25% Increase Over ...
CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and to the Board’s Audit Committee. “Dr. Gardner’s very broad and deep expertise in medicine, biotechnology, and corporate investing and governance is an ideal skill set for the CohBar Board as we strategically advance our portfolio and pipeline of mitochondrial peptides and disease targets,” said Albion Fitzgerald, Chairman of the Board.
Parnell Delivers 39% Revenue Growth and a $5.9 Million Year-to-Date Improvement in EBITDA as at the Third Quarter of 2018 Compared to the Same Period in 2017, Consolidates the Return to Profitability, ...
Parnell Delivers 32% Revenue Growth And A $4.0 Million Improvement In EBITDA In The First Six Months Of 2018 Compared To The Same Period In 2017, Returns To Profitability For The First Time Post-IPO And ...
SYDNEY, AUSTRALIA / ACCESSWIRE / July 31, 2018 / Parnell Pharmaceuticals Holdings Ltd. (OTC PINK: PARNF) ("Parnell" or the "Company"), a fully integrated pharmaceutical company focused ...